Find Funding Opportunities

This Funding Opportunity Announcement (FOA) is issued as an initiative of the NIH Blueprint for Neuroscience Research. The Neuroscience Blueprint is a collaborative framework through which 16 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/). The goal of this FOA is to encourage research grant applications that propose to develop or substantially modify existing cutting edge technologies that will advance glial cell research, discovery-based research on glial cell diversity, development and/or function in the central (CNS) and peripheral (PNS) nervous systems. The primary objective of this FOA is to remove barriers to glial cell research that are due to the scarcity of tools, methods and technologies to target and identify glial cells in a rigorous manner. Applications should aim to transform the field of glial cell research by generating tools that will be widely used throughout the neuroscience community. Research supported by this initiative will (i) provide new tools for manipulating and identifying glial cells based on their heterogeneity, developmental stage or functional state; and /or (ii) tools to allow investigation of glial function and processes, thus contributing to our understanding of normal and abnormal neural function.

This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund (Common Fund) and participating NIH Institute(s) and Center(s), invites applications from foreign Institutions in African countries who wish to develop the study of genomic/genetic/environmental contributors of human health and disease within Africa, using cutting edge research tools to understand health and diseases affecting African populations more completely and increase capacity for biomedical research, in terms of building infrastructure (including data and research resources), genomic proficiency of researchers and numbers of trainees.In partnership with the Wellcome Trust, the H3Africa initiative is focused on supporting these efforts as part of an effort to promote sustainable research in Africa that will promote health and combat disease. The purpose of this FOA is to call for applications for research projects. Awards will focus on supporting research on the genetic/environmental contributors to health and disease in Africa that fall within the mission of the NIH, which is to seek fundamental knowledge about the nature and behavior of living systems and to apply that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability.

The National Institute of Neurological Disorders and Stroke (NINDS) invites new and renewal applications for the Morris K. Udall Centers of Excellence for Parkinsons Disease Research program. The overarching goal of the specialized Udall Centers program is to establish a network of Centers that work independently as well as collaboratively to define the causes of and discover improved treatments for Parkinsons disease (PD). A more immediate goal for each Center is to rapidly advance synergistic basic, translational and clinical research programs while serving as local resources and national leaders in PD research.

This Funding Opportunity Announcement (FOA) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on assays that provide new insight into important disease targets and processes..

This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes. It is expected that applicants will have in hand the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on assays that provide new insight into important disease targets and processes..

This NIH Funding Opportunity Announcement (FOA), supported by funds from the participating NIH Institutes and Centers (ICs), invites applications from foreign Institutions in Sub-Saharan African countries who are a part of the Medical Education Partnership Initiative Network of institutions (http://www.fic.nih.gov/Grants/Search/Pages/Awards-Program-MEPI.aspx) to develop research capacity and research education opportunities in priority health areas related to and/or beyond HIV/AIDS. These opportunities are intended to strengthen medical education systems in the countries in which they exist, and build clinical and research capacity in priority health areas related to and/or beyond HIV/AIDS.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to pursue translational and pilot clinical studies for neural prosthetics. The program will utilize the cooperative agreement mechanism to enable support for milestone-driven projects for the development and demonstration of clinically-useful neural prosthetic devices. Activities supported in this program include implementation of clinical prototype devices, preclinical safety and efficacy testing, design verification and validation activities, pursuit of regulatory approval for clinical study, and proof-of-concept or pilot clinical studies.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue translational and pilot clinical studies for neural prosthetics. The program will utilize the cooperative agreement mechanism to enable support for milestone-driven projects for the development and demonstration of clinically-useful neural prosthetic devices. Activities supported in this program include implementation of clinical prototype devices, preclinical safety and efficacy testing, design verification and validation activities, pursuit of regulatory approval for clinical study, and proof-of-concept or pilot clinical studies.

The National Institute of Neurological Disorders and Stroke (NINDS) invites applications for participation in the Stroke Prevention/Intervention Research Program (SPIRP). The goal of the program is to develop high-impact stroke disparities interventions and research projects that have the ability to reduce stroke disparities in minority communities in the United States using effective and culturally appropriate methods. Required components include: (1) an intervention or prevention project to reduce stroke disparities in minority communities; (2) at least one additional stroke disparities research project that will address knowledge gaps or opportunities to improve the understanding of stroke disparities (race/ethnicity, rural, or low socio-economic); (3) resource-related cores that are essential to accomplishing the Specific Aims of the proposed research project and provide training/education.

This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund (Common Fund) and participating NIH Institute(s) and Center(s), invites applications for the development of human multi-cellular models that can replicate aspects of human organ physiology. Disease pathogenesis, cell-type diversity, genomic complexity, monitoring of cell to cell and cell to matrix interactions and microenvironment regulation are key aspects to be addressed by these model systems. The multi-cellular architecture will represent characteristics of the organ being modeled and will demonstrate reproducible cellular signatures and functional outputs under physiological conditions. It is anticipated that these human cell/tissue models could lead to the development and commercialization of cellular 3D modules that would eventually become part of larger organ systems targeted for rapid and high fidelity safety and efficacy evaluation of candidate therapeutics. Applications unresponsive to this FOA are those developing 3D tissues for transplantation, engineering non-human tissue models or developing simple 3D models that do not go significantly beyond those currently available and in use. Funds from the NIH will be made available through the U18 cooperative agreement award mechanism. These 2 year awards will support studies to develop multi-cellular models representative of the cellular diversity, genomic complexity, cellular architecture and function of the tissues or organs being modeled.Multi-cellular models that reflect disease pathologies including but not limited to cardiomyopathy, endocrinopathies, type 1 and type 2 diabetes, inflammatory bowel disease, pancreatitis, autoimmunity, fibrosis, muscular dystrophies, neuromuscular disorders, neurodevelopmental disorders, seizures, pulmonary hypertension and cystic fibrosis are of particular interest. The NIH is collaborating with the Defense Advanced Research Projects Agency (DARPA) and the US Food and Drug Administration (FDA) to enable coordination of separate but parallel efforts in development of in vitro microphysiological systems as they relate to regulatory science.